Shire has entered into an agreement to acquire New River Pharmaceuticals, Inc. for approximately $2.6 billion in cash. “We are delighted to be entering into this transaction with Shire, which will assume full responsibility for the commercialization of Vyvanse, as well as the development of our other pipeline compounds,” said Randal J. Kirk, New River’s founder, chairman and chief executive officer. “We are proud of the accomplishments of the New River team during t...